bioTheranostics
San Diego, US · Founded 2008 · Delaware corporation · 97 employees on LinkedIn · 3 known investors
Find your way into bioTheranostics
Biotheranostics develops proprietary genomic assays used to support personalized disease management in oncology. The company was acquired by Hologic in February 2021.
Founders & leadership
NB
Nicholas BarthelemyExecutive
Board
DK
EB
AS
Investors · 3
Reported raises · per SEC filings
Form D private placements$20M disclosed across 1 round · 2016
▶$20MraisedFeb 2016 · 4 investors · Other Health CareRule 506(b)
▶$20MraisedFeb 2016 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas BarthelemyExecutive Officer, Director, Promoter
- David KabakoffDirector
- Eric BednarskiDirector
- Alejandro SanchezDirector
- Offering amount
- $32M
- Amount sold
- $20M
- Sales commissions
- $1.6M
- Placement agents
- Piper Jaffray & Co.
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does bioTheranostics do?
- Biotheranostics develops proprietary genomic assays used to support personalized disease management in oncology. The company was acquired by Hologic in February 2021.
- Who are bioTheranostics's investors?
- bioTheranostics's investors include Evidity Health Capital, HealthQuest Capital, MVM Life Science Partners.
- How much funding has bioTheranostics raised?
- bioTheranostics has disclosed $20M raised across 1 round.
- Where is bioTheranostics headquartered?
- bioTheranostics is headquartered in San Diego, US.